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Abstract
Background: Basal Cell Carcinoma (BCC) is the most common carcinoma in humans. It accounts
for 20% of carcinomas in men and 10–15% of carcinomas in women. Despite its high incidence,
metastatic events are exceedingly rare. The reported frequency of metastatic dissemination is
estimated at 0.0028–0.5 percent. Once metastasis is detected, there is a high mortality rate of 50%
within 8 months.
Methods: In this study, we present a case of simultaneous lung and parotid metastases of giant
BCC primary located on the right medial canthus of a 62 year old female.
Results: Examination of the tumor located on the medial canthus obtained showed "adenoid
BCC". Computed tomography (CT) was performed to evaluate parotid region for evaluation of
parotid gland and chest. Parotid and lung metastasis were detected in CT. Routine labarotory tests
and radiological investigations were done. There was no abnormal finding. We also investigated this
patient with a bone scan (normal), abdominal and cranial CT scans (also normal).
Conclusion: Although metastasis of BCC is a very rare condition, this study reports a case of
simultaneous parotid gland and lung metastasis originating from a giant BCC primary that was
located on the right inner canthus of a 62 year old female.
Background
Basal cell carcinoma (BCC) is the most common carci-
noma in humans and accounts for 20% of carcinomas in
men and 10–15% of carcinomas in women. Approxi-
mately 75–86% of primary BCCs are found on the head or
neck. The most common location on the head is the nose,
specifically the nasal tip and alae. It constitutes 90% of
periorbital malignancies [1,2]. Sun exposure is the pri-
mary etiologic agent for the development of BCC. The
tumors are more frequent in individuals with fair
complexions.
BCC arising on the medial canthus tends to be deep and
invasive and may result in perineural extension and loss
of optic nerve function. Pieh et al reported that the highest
recurrence rates of BCC following attempted excision,
(approximately 60%), was seen with lesions arising from
the medial canthus since these lesions tend to be more
invasive and difficult to manage [3]. Reclusive patients or
patients who neglect the lesions for long periods of time
are more likely to have giant, invasive tumors [4]. Giant
BCC, defined as lesions more than 5 cm at its largest
diameter, are rare forms of BCC [4]. Giant BCCs more
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commonly appear on the trunk and display a more aggres-
sive behavior, resulting in local invasion and metastasis.
The reported incidence of metastatic BCC ranges from
0.03 % to 0.55 [5]. We report a case of simultaneous lung
and parotid gland metastases of giant BCC located on
medial canthus.
Case report
A 62-year-old woman was referred to the Plastic and
Reconstructive Surgery Department for treatment of a
bleeding exophytic tumor located on the right inner can-
thus. She had had the lesion for approximately 11 years.
Initially, the patient was treated with excision and primary
closure ten years ago. At this time the tumor had a diame-
ter of 5 cm. The tumor was diagnosed as adenoid BCC
microscopically and surgical margins were tumor-posi-
tive. The patient was operated on two years later when the
diameter of the recurrent tumor was 15 mm. Histological
examination of this second specimen revealed an "ade-
noid BCC" with clear surgical margins.
Although the tumor recurred again after the second exci-
sion, the patient neglected medical advice and did not
undertake any treatment (Figure 1). More recently, how-
ever, the tumor began growing rapidly and became hem-
orrhagic. On examination the lesion was located on the
right inner canthus and involved 1/3 of the eyelid. The
size of tumor was approximately 55 mm × 45 mm. Visual
functions of the patient were normal. However, a fixed
mass developed in the patient's periauricular area six
months ago (Figure 2), although there were no palpable
cervical nodes. We therefore investigated this region with
computed tomography (CT), which revealed a tumor
involving the right orbital structures extending to the eth-
moidal cells. The tumor also involved the right parotid
gland and multiple cervical lymph nodes.
We also investigated this patient with a bone scan (nor-
mal), abdominal and cranial CT scans (also normal) and
a thoracic CT. Multiple metastatic lesions were seen in the
chest CT (Figure 3).
Giant BCC located on the inner canthus Figure 1
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Examinations of the cardiovascular, gastrointestinal, neu-
rological, urogenital and hematological systems and other
parts of the skin were performed by physical and routine
laboratory and radiological techniques. There were no
abnormal findings. Biopsy was performed from the tumor
located on the inner canthus and revealed "adenoid basal
cell carcinoma" (Figure 4). Also, Fine needle biopsies were
performed on the parotid and pulmonary lesions which
confirmed the presence of adenoid BCC in these regions.
The patient did not accept the offer of surgical treatment
for the tumor on the inner canthus. She was referred to the
Oncology Department and treated with radiotherapy and
chemotherapy. The patient received approximately 6000
cGy of external beam radiation over 3 weeks totally. Also,
chemotherapy was initiated with cisplatin and 5-fluoru-
racil. She was followed up with physical examination and
CT scans for six months and there were no metastases to
other organs. She is still being followed.
Discussion
Spates et al. noted that metastatic BCC was first reported
in 1894 [6]. As outlined by Lattes and Kessler, metastatic
basal cell carcinoma is defined by the following criteria:
1) the primary tumor must occur in skin containing hair
follicles and not the mucous membranes;
2) metastasis cannot be by simple extension, but occur-
ring at a site distant from the primary tumor;
3) the primary tumor and the metastasis must have simi-
lar histologic appearances of basal cell carcinoma; and
4) squamous cell features must not be present in the
lesions [7,8]. The case presented here satisfied these three
criteria. More than 300 cases of metastatic BCC have been
reported in the literature. Two-thirds of metastatic BCCs
arise from primary tumors on the face, with the ear being
Involvement of the parotid gland of the patient Figure 2
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CT scan of the chest of the patient Figure 3
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the most common location. Higher rates of metastasis
also occur from primary lesions on the scalp and genitalia
[9-11]. Primary BCC metastasizes through hematogenous
and lymphatic routes. As was the case with our patient,
metastasis to the lymph nodes has been estimated to
occur in 70% of cases. The most common organs involved
in hematogenous spread are lungs, bone, and skin
[12,13].
While the usual BCC that gives rise to metastases is a large,
ulcerated, locally invasive BCC of the head and neck that
recurs despite repeated surgical procedures or radiother-
apy, these features are not absolute prerequisites for
metastasis [14]. Immunosupression may be a factor in the
pathogenesis of the metastasis of BCC, but there was no
finding suggestive of immune system abnormality in the
case presented here [14]. Some authors have suggested
that immunosuppression or impaired cell-mediated
immunity (including AIDS) may predispose to BCC and
BCC metastasis [15-17]. BCC usually has multiple skin
recurrences before metastases become evident as in the
case presented here [18]. BCCs with any of the following:
long duration, location in the mid face or ear, a diameter
larger than 2 cm, with aggressive histological subtype, pre-
vious treatment, neglected, or a history of radiation expo-
sure, should be considered "high risk [19]. Although giant
BCC is commonly located on the trunk, Takemato et al
reported a case of with giant basal cell carcinoma which
invaded the orbital tissue and anterior skull base [4]. They
concluded that giant basal cell carcinomas have aggressive
character to destroy tissue and more metastatic potential.
Many investigators have reported that radical treatment
with a wide excision of the tumor at an early stage is essen-
tial to treat a potentially aggressive BCC. Takemato et al
used a free rectus abdominis musculocutaneous flap in
the treatment of giant BCC which invaded the orbital tis-
sue [4].
Tumors greater than 3 cm in diameter have a 2 % inci-
dence of metastasis and/or death. This increases to 25% in
those lesions more than 5 cm in diameter and to 50% in
lesions more than 10 cm in diameter [20]. The prognosis
of metastatic BCC is extremely poor. Once metastasis is
detected, there is a high mortality rate of 50% within 8
months [20]. This poor outcome has led to the use of sys-
temic chemotherapy in a number of individual cases. Sev-
eral chemotherapeutic agents that have been used in
metastatic BCC, including fluorouracil and combination
of vincristine, bleomycine and prednisone [18].Kaufman
suggested that cisplatin, alone or in combination is prob-
ably the most active in metastatic BCC [21]. Recently, Jef-
ford et al presented their experience in the treatment of
metastatic BCC [22]. According to their study, systemic
chemotherapy with cisplatin and paclitaxel provided pal-
liative benefit to their patient with acceptable toxicity and
conclude that the regimen is a reasonable choice for the
rare patient presenting with metastatic BCC. About half of
metastatic BCCs have metastasis to lymph nodes as the
first site, but hematogenous route to lung and bone is also
equally represented [23]. Robinson and Dahiya reported
a case of BCC with pulmonary and lymph node metastasis
causing death [14]. BCC located on the nose, eyebrow,
ear, nose, and temple frequently metastasizes to the
parotid and lymph nodes of neck [24]. To the best of our
knowledge this report is the first to present simultaneous
lung and parotid gland metastases of giant BCC.
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